ARQT (Arcutis Biotherapeutics, Inc.) Stock Financials & Earnings

ARQTArcutis Biotherapeutics, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$376M

Net Income (TTM)-$16M

EPS (TTM)-$0.14

Free Cash Flow (TTM)-$6M

Gross Margin90.2%

Op. Margin-3.3%

Net Margin-4.3%

FCF Margin-1.7%

P/S Ratio (TTM)8.2x

P/E Ratio (TTM)—

YoY Rev Growth+91.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$3M	$2M	-$76M
Q2 23	$5M	$4M	-$67M
Q3 23	$38M	$37M	-$37M
Q4 23	$14M	$11M	-$61M
Q1 24	$50M	$46M	-$32M
Q2 24	$31M	$27M	-$50M
Q3 24	$45M	$39M	-$39M
Q4 24	$71M	$64M	-$8M
Q1 25	$66M	$57M	-$25M
Q2 25	$82M	$74M	-$15M
Q3 25	$99M	$91M	$9M
Q4 25	$130M	$118M	$18M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$35M	$6M	$37M	—
Q2 23	$25M	$46M	—	—
Q3 23	$26M	$48M	—	—
Q4 23	$24M	—	—	$49M
Q1 24	$23M	—	—	$55M
Q2 24	$19M	—	—	$58M
Q3 24	$20M	—	—	$59M
Q4 24	$14M	—	—	$58M
Q1 25	$18M	—	—	$64M
Q2 25	$19M	—	—	$69M
Q3 25	$20M	—	—	$62M
Q4 25	$20M	—	—	$79M

Revenue Segments

Quarter	Other Revenue	Product
Q3 23	$30M	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$81M	$251M	$332M
Q2 23	$105M	$164M	$269M
Q3 23	$107M	$120M	$227M
Q4 23	$88M	$183M	$272M
Q1 24	$191M	$214M	$404M
Q2 24	$85M	$278M	$363M
Q3 24	$135M	$196M	$331M
Q4 24	$71M	$157M	$228M
Q1 25	$53M	$145M	$198M
Q2 25	$73M	$118M	$191M
Q3 25	$47M	$144M	$191M
Q4 25	$43M	$178M	$221M

Shares Outstanding

Revenue Per Employee

Revenue / Employee